EGFR and lung carcinoma: A previous study revealed that osimertinib can inhibit the growth of transgenic lung cancer mouse models harboring mouse EGFR exon19 deletion (mDEL) tumors with T790I mutation; however, these tumors acquired resistance to osimertinib and regrew 2 months after treatment (9).